Startup entity
Every one of those 1 sits in a single category, market-trends. Platelet-Rich Plasma (PRP) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 2.3 across the same-window beat baseline.
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Platelet-Rich Plasma (PRP) is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 2 original sources per story, versus 2.3 across the same-window beat baseline. The 6 average consequence score is below the beat benchmark of 6.6 in the same window. We currently track 1 Startup story that mention Vyansa Intelligence, all published on March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 48 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Vyansa Intelligence. Shared-story counts are live from our verified record — not editorial picks.
The global animal regenerative therapies market is projected to reach $870 million by 2032, fueled by breakthroughs in stem cell and PRP treatments. This growth reflects a broader venture shift toward high-margin veterinary biotechnology as pet owners demand human-grade medical outcomes for companion animals.
Vyansa Intelligence is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
